The kinin B1 receptor and inflammation: new therapeutic target for cardiovascular disease

Current Opinion in Pharmacology

Volumn 9, Issue 2, 2009, Pages 125-131

  Duchene, Johan ^a   Ahluwalia, Amrita ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; KALLIKREIN; KININ; MONOCYTE CHEMOTACTIC PROTEIN 1; SSR 240612; SULFONAMIDE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ENDARTERECTOMY; DRUG BIOAVAILABILITY; DRUG TARGETING; HUMAN; HYPERALGESIA; INFLAMMATION; KIDNEY DISEASE; KIDNEY FIBROSIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OBESITY; PATHOGENESIS; PAW EDEMA; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN FUNCTION; REVIEW; SKIN EDEMA; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BRADYKININ; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KALLIDIN; KIDNEY DISEASES; NEUTROPHIL INFILTRATION; RECEPTOR, BRADYKININ B1;

EID: 62249153952     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.11.011     Document Type: Review

References (49)

1. Leeb-Lundberg L.M., Marceau F., Muller-Esterl W., Pettibone D.J., and Zuraw B.L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57 (2005) 27-77
2. Bhoola K.D., Figueroa C.D., and Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44 (1992) 1-80
3. Decarie A., Raymond P., Gervais N., Couture R., and Adam A. Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. Am J Physiol 271 (1996) H1340-H1347
4. Marceau F., Sabourin T., Houle S., Fortin J.P., Petitclerc E., Molinaro G., and Adam A. Kinin receptors: functional aspects. Int Immunopharmacol 2 (2002) 1729-1739
5. Ahluwalia A., and Perretti M. B1 receptors as a new inflammatory target. Could this B the 1?. Trends Pharmacol Sci 20 (1999) 100-104
6. Prado G.N., Taylor L., Zhou X., Ricupero D., Mierke D.F., and Polgar P. Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. J Cell Physiol 193 (2002) 275-286
7. Ghosh S., and Hayden M.S. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8 (2008) 837-848
8. Schanstra J.P., Bataille E., Marin Castano M.E., Barascud Y., Hirtz C., Pesquero J.B., Pecher C., Gauthier F., Girolami J.P., and Bascands J.L. The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J Clin Invest 101 (1998) 2080-2091
9. Ahluwalia A., and Perretti M. Involvement of bradykinin B1 receptors in the polymorphonuclear leukocyte accumulation induced by IL-1 beta in vivo in the mouse. J Immunol 156 (1996) 269-274
10. Pesquero J.B., Araujo R.C., Heppenstall P.A., Stucky C.L., Silva Jr. J.A., Walther T., Oliveira S.M., Pesquero J.L., Paiva A.C., Calixto J.B., et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 97 (2000) 8140-8145
11. McLean P.G., Ahluwalia A., and Perretti M. Association between kinin B(1) receptor expression and leukocyte trafficking across mouse mesenteric postcapillary venules. J Exp Med 192 (2000) 367-380
12. 1R-induced leukocyte recruitment with chemokine synthesis, in particular the evidence implicated endothelial CXCL5.13.
13. Vianna R.M., and Calixto J.B. Characterization of the receptor and the mechanisms underlying the inflammatory response induced by des-Arg9-BK in mouse pleurisy. Br J Pharmacol 123 (1998) 281-291
14. McLean P.G., Perretti M., and Ahluwalia A. Kinin B(1) receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res 48 (2000) 194-210
15. Regoli D.C., Marceau F., and Lavigne J. Induction of B1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol 71 (1981) 105-115
16. Churchill L., and Ward P.E. Relaxation of isolated mesenteric arteries by des-Arg9-bradykinin stimulation of B1 receptors. Eur J Pharmacol 130 (1986) 11-18
17. Rhaleb N.E., Dion S., Barabe J., Rouissi N., Jukic D., Drapeau G., and Regoli D. Receptors for kinins in isolated arterial vessels of dogs. Eur J Pharmacol 162 (1989) 419-427
18. McLean P.G., Perretti M., and Ahluwalia A. Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9bradykinin-induced coronary vasodilation. Br J Pharmacol 128 (1999) 275-282
19. Wedmore C.V., and Williams T.J. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature 289 (1981) 646-650
20. Dianzani C., Collino M., Lombardi G., Garbarino G., and Fantozzi R. Substance P increases neutrophil adhesion to human umbilical vein endothelial cells. Br J Pharmacol 139 (2003) 1103-1110
21. Ehrenfeld P., Millan C., Matus C.E., Figueroa J.E., Burgos R.A., Nualart F., Bhoola K.D., and Figueroa C.D. Activation of kinin B1 receptors induces chemotaxis of human neutrophils. J Leukoc Biol 80 (2006) 117-124
22. Marceau F., Hess J.F., and Bachvarov D.R. The B1 receptors for kinins. Pharmacol Rev 50 (1998) 357-386
23. Raidoo D.M., Ramsaroop R., Naidoo S., Muller-Esterl W., and Bhoola K.D. Kinin receptors in human vascular tissue: their role in atheromatous disease. Immunopharmacology 36 (1997) 153-160
24. Legedz L., Randon J., Sessa C., Baguet J.P., Feugier P., Cerutti C., Bourdillon M.C., and Bricca G. Induction of tissue kallikrein in human carotid atheroma does not lead to kallikrein-kinins pathway activation. J Hypertens 23 (2005) 359-366
25. Kaschina E., Stoll M., Sommerfeld M., Steckelings U.M., Kreutz R., and Unger T. Genetic kininogen deficiency contributes to aortic aneurysm formation but not to atherosclerosis. Physiol Genomics 19 (2004) 41-49
26. Merkulov S., Zhang W.M., Komar A.A., Schmaier A.H., Barnes E., Zhou Y., Lu X., Iwaki T., Castellino F.J., Luo G., et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 111 (2008) 1274-1281
27. Ohashi N., Matsumori A., Furukawa Y., Ono K., Okada M., Iwasaki A., Miyamoto T., Nakano A., and Sasayama S. Role of p38 mitogen-activated protein kinase in neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 20 (2000) 2521-2526
28. Christopher J., Velarde V., and Jaffa A.A. Induction of B(1)-kinin receptors in vascular smooth muscle cells: cellular mechanisms of map kinase activation. Hypertension 38 (2001) 602-605
29. Ceravolo G.S., Fernandes L., Munhoz C.D., Fernandes D.C., Tostes R.C., Laurindo F.R., Scavone C., Fortes Z.B., and Carvalho M.H. Angiotensin II chronic infusion induces B1 receptor expression in aorta of rats. Hypertension 50 (2007) 756-761
30. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
31. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P., and Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
32. Chien S. Mechanotransduction and endothelial cell homeostasis: the wisdom of the cell. Am J Physiol Heart Circ Physiol 292 (2007) H1209-H1224
33. Malek A.M., Alper S.L., and Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 282 (1999) 2035-2042
34. Zernecke A., Bot I., Djalali-Talab Y., Shagdarsuren E., Bidzhekov K., Meiler S., Krohn R., Schober A., Sperandio M., Soehnlein O., et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 102 (2008) 209-217. This study demonstrated an essential role of neutrophil recruitment in the development of atheromatous plaque in the athero-prone APOE knockout mouse.
35. van Leeuwen M., Gijbels M.J., Duijvestijn A., Smook M., van de Gaar M.J., Heeringa P., de Winther M.P., and Tervaert J.W. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/- mice. Arterioscler Thromb Vasc Biol 28 (2008) 84-89. This study used imuunohistochemical and biochemical techniques demonstrating recruiment of neutrophils at sites of atheroma formation in athero-prone mouse models.
36. Frangogiannis N.G. Chemokines in ischemia and reperfusion. Thromb Haemost 97 (2007) 738-747
37. Sean Eardley K., and Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int 68 (2005) 437-455
38. Wang P.H., Campanholle G., Cenedeze M.A., Feitoza C.Q., Goncalves G.M., Landgraf R.G., Jancar S., Pesquero J.B., Pacheco-Silva A., and Camara N.O. Bradykinin B1 receptor antagonism is beneficial in renal ischemia-reperfusion injury. PLoS ONE 3 (2008) e3050
39. Wang P.H., Cenedeze M.A., Pesquero J.B., Pacheco-Silva A., and Camara N.O. Influence of bradykinin B1 and B2 receptors in the immune response triggered by renal ischemia-reperfusion injury. Int Immunopharmacol 6 (2006) 1960-1965
40. Kakoki M., McGarrah R.W., Kim H.S., and Smithies O. Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 104 (2007) 7576-7581
41. Klein J., Gonzalez J., Duchene J., Esposito L., Pradere J.P., Neau E., Delage C., Calise D., Ahluwalia A., Carayon P., et al. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J 23 (2009) 134-142. Demonstration of reversal of renal damage by oral administration of the non-peptidic antagonist SSR240612 in a murine model of chronic obstructive renal injury and association of this effect with inhibition of CCL-2 production and monocyte/macrophage recruitment/activation.
42. Campos M.M., Leal P.C., Yunes R.A., and Calixto J.B. Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain. Trends Pharmacol Sci 27 (2006) 646-651
43. Hawkinson J.E., Szoke B.G., Garofalo A.W., Hom D.S., Zhang H., Dreyer M., Fukuda J.Y., Chen L., Samant B., Simmonds S., et al. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. J Pharmacol Exp Ther 322 (2007) 619-630
44. Wood M.R., Kim J.J., Han W., Dorsey B.D., Homnick C.F., DiPardo R.M., Kuduk S.D., MacNeil T., Murphy K.L., Lis E.V., et al. Benzodiazepines as potent and selective bradykinin B1 antagonists. J Med Chem 46 (2003) 1803-1806
45. Costa R., Fernandes E.S., Menezes-de-Lima Jr. O., Campos M.M., and Calixto J.B. Effect of novel selective non-peptide kinin B(1) receptor antagonists on mouse pleurisy induced by carrageenan. Peptides 27 (2006) 2967-2975. This is an interesting study that compared different new non-peptidic B1R antagonists including compound 12 and SSR240612 and demonstrated their inhibitory effect on neutrophil recruitment.
46. Ritchie T.J., Dziadulewicz E.K., Culshaw A.J., Muller W., Burgess G.M., Bloomfield G.C., Drake G.S., Dunstan A.R., Beattie D., Hughes G.A., et al. Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core. J Med Chem 47 (2004) 4642-4644
47. Fox A., Kaur S., Li B., Panesar M., Saha U., Davis C., Dragoni I., Colley S., Ritchie T., Bevan S., et al. Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor. Br J Pharmacol 144 (2005) 889-899
48. Gougat J., Ferrari B., Sarran L., Planchenault C., Poncelet M., Maruani J., Alonso R., Cudennec A., Croci T., Guagnini F., et al. SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]pheny l)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 309 (2004) 661-669
49. Mori M.A., Araujo R.C., Reis F.C., Sgai D.G., Fonseca R.G., Barros C.C., Merino V.F., Passadore M., Barbosa A.M., Ferrari B., et al. Kinin B1 receptor deficiency leads to leptin hypersensitivity and resistance to obesity. Diabetes 57 (2008) 1491-1500